Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409201 | 0.90 | KDM4E (0.43) | KDM4EALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL12409204 | 0.85 | KDM4E (0.52) | KDM4EALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL12409196 | 0.85 | KDM4E (0.53) | ESRRGKDM4EALDH1A1MAPK1TDP1 | |
| SCHEMBL12409195 | 0.81 | PTGER1 (0.43) | KDM4EALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL12409199 | 0.74 | KDM4E (0.53) | KDM4EALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL10184817 | 0.71 | CYP1A2 (0.59) | ESRRGALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL2173939 | 0.69 | KDM4E (0.61) | KDM4EALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL278403 | 0.67 | LMNA (0.54) | KDM4EALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL12409218 | 0.67 | SERPINE1 (0.42) | KDM4EALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL12409202 | 0.67 | KDM4E (0.55) | KDM4EALDH1A1MAPK1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, ALDH1A2 | ESRRG 597/4885KDM4E 4096/4885ALDH1A1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.